Skip to main content
main-content
Erschienen in: CME 3/2015

22.03.2015 | CME Fortbildung

Diagnostik und Behandlung von Vorhofflimmern

Aktuelle Empfehlungen für die Praxis

verfasst von: Prof. Dr. Paulus Kirchhof

Erschienen in: CME | Ausgabe 3/2015

Einloggen, um Zugang zu erhalten

Zusammenfassung

Vorhofflimmern ist die mit Abstand häufigste anhaltende Herzrhythmusstörung, die Diagnose wird im Elektrokardiogramm (EKG) gestellt. Vorhofflimmern tritt gehäuft im hohen Alter auf. Die Patienten benötigen fast immer eine orale Antikoagulation und eine frequenzregulierende Therapie. Ziel ist eine Herzfrequenz in Ruhe von 100–110 Schläge/min. Wenn die Patienten unter der Symptomatik des Vorhofflimmerns leiden, ist eine rhythmuserhaltende Therapie mit Antiarrhythmika, Kardioversion oder Katheterablation indiziert. Ausschlaggebend für die Wahl zwischen diesen Verfahren sollten Sicherheitserwägungen sein, weniger die erwartete Effektivität. Ob der Erhalt des Sinusrhythmus auch die Prognose bei Vorhofflimmern verbessert, ist Gegenstand laufender Studien. Die Antikoagulation und die frequenzregulierende Behandlung müssen unabhängig vom scheinbaren zeitweiligen Erfolg einer rhythmuserhaltenden Maßnahme fortgesetzt werden.
Literatur
[1]
Zurück zum Zitat Camm AJ, Kirchhof P, Lip GY et al (2010) Guidelines for the management of atrial fibrillation: the task force for the management of atrial fibrillation of the European Society of Cardiology (ESC). Eur Heart J 31:2369–2429 CrossRefPubMed Camm AJ, Kirchhof P, Lip GY et al (2010) Guidelines for the management of atrial fibrillation: the task force for the management of atrial fibrillation of the European Society of Cardiology (ESC). Eur Heart J 31:2369–2429 CrossRefPubMed
[2]
Zurück zum Zitat Camm AJ, Lip GY, De Caterina R et al (2012) 2012 focused update of the ESC guidelines for the management of atrial fibrillation: an update of the 2010 ESC guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association. Eur Heart J 33:2719–2747 CrossRefPubMed Camm AJ, Lip GY, De Caterina R et al (2012) 2012 focused update of the ESC guidelines for the management of atrial fibrillation: an update of the 2010 ESC guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association. Eur Heart J 33:2719–2747 CrossRefPubMed
[3]
Zurück zum Zitat Nabauer M, Gerth A, Limbourg T et al (2009) The registry of the German competence NETwork on atrial fibrillation: patient characteristics and initial management. Europace 11:423–434 CrossRefPubMedCentralPubMed Nabauer M, Gerth A, Limbourg T et al (2009) The registry of the German competence NETwork on atrial fibrillation: patient characteristics and initial management. Europace 11:423–434 CrossRefPubMedCentralPubMed
[4]
Zurück zum Zitat Kirchhof P, Auricchio A, Bax J et al (2007) Outcome parameters for trials in atrial fibrillation: executive summary: recommendations from a consensus conference organized by the German Atrial Fibrillation Competence NETwork (AFNET) and the European Heart Rhythm Association (EHRA). Eur Heart J 28:2803–2817 CrossRefPubMed Kirchhof P, Auricchio A, Bax J et al (2007) Outcome parameters for trials in atrial fibrillation: executive summary: recommendations from a consensus conference organized by the German Atrial Fibrillation Competence NETwork (AFNET) and the European Heart Rhythm Association (EHRA). Eur Heart J 28:2803–2817 CrossRefPubMed
[5]
Zurück zum Zitat Dorian P, Cvitkovic SS, Kerr CR et al (2006) A novel, simple scale for assessing the symptom severity of atrial fibrillation at the bedside: the CCS-SAF scale. Can J Cardiol 22:383–386 CrossRefPubMedCentralPubMed Dorian P, Cvitkovic SS, Kerr CR et al (2006) A novel, simple scale for assessing the symptom severity of atrial fibrillation at the bedside: the CCS-SAF scale. Can J Cardiol 22:383–386 CrossRefPubMedCentralPubMed
[6]
Zurück zum Zitat Samol A, Masin M, Gellner R et al (2013) Prevalence of unknown atrial fibrillation in patients with risk factors. Europace 15(5):657–662 CrossRefPubMed Samol A, Masin M, Gellner R et al (2013) Prevalence of unknown atrial fibrillation in patients with risk factors. Europace 15(5):657–662 CrossRefPubMed
[7]
Zurück zum Zitat Kaleschke G, Hoffmann B, Drewitz I et al (2009) Prospective, multicentre validation of a simple, patient-operated electrocardiographic system for the detection of arrhythmias and electrocardiographic changes. Europace 11:1362–1368 CrossRefPubMed Kaleschke G, Hoffmann B, Drewitz I et al (2009) Prospective, multicentre validation of a simple, patient-operated electrocardiographic system for the detection of arrhythmias and electrocardiographic changes. Europace 11:1362–1368 CrossRefPubMed
[8]
Zurück zum Zitat Kirchhof P, Curtis AB, Skanes A et al (2013) Atrial fibrillation guidelines across the Atlantic: a comparison of the current recommendations of the European Society of Cardiology/European Heart Rhythm Association/European Association of Cardiothoracic Surgeons, the American College of Cardiology Foundation/American Heart Association/Heart Rhythm Society, and the Canadian Cardiovascular Society. Eur Heart J 34:1471–1474 CrossRefPubMed Kirchhof P, Curtis AB, Skanes A et al (2013) Atrial fibrillation guidelines across the Atlantic: a comparison of the current recommendations of the European Society of Cardiology/European Heart Rhythm Association/European Association of Cardiothoracic Surgeons, the American College of Cardiology Foundation/American Heart Association/Heart Rhythm Society, and the Canadian Cardiovascular Society. Eur Heart J 34:1471–1474 CrossRefPubMed
[9]
Zurück zum Zitat Engdahl J, Andersson L, Mirskaya M, Rosenquist M (2013) Stepwise screening for atrial fibrillation in a 75-year-old population — implications for stroke prevention. Circulation 127:930–937 CrossRefPubMed Engdahl J, Andersson L, Mirskaya M, Rosenquist M (2013) Stepwise screening for atrial fibrillation in a 75-year-old population — implications for stroke prevention. Circulation 127:930–937 CrossRefPubMed
[10]
Zurück zum Zitat Vanassche T et al (2014) Risk of ischaemic stroke according to pattern of atrial fibrillation: analysis of 6563 aspirin-treated patients in ACTIVE-A and AVERROES. Eur Heart J (Epub ahead of print) Vanassche T et al (2014) Risk of ischaemic stroke according to pattern of atrial fibrillation: analysis of 6563 aspirin-treated patients in ACTIVE-A and AVERROES. Eur Heart J (Epub ahead of print)
[11]
Zurück zum Zitat Watson T, Shantsila E, Lip GY (2009) Mechanisms of thrombogenesis in atrial fibrillation: Virchow’s triad revisited. Lancet 373:155–166 CrossRefPubMed Watson T, Shantsila E, Lip GY (2009) Mechanisms of thrombogenesis in atrial fibrillation: Virchow’s triad revisited. Lancet 373:155–166 CrossRefPubMed
[12]
Zurück zum Zitat Kirchhof P (2012) How do we balance risk and benefit in a population at risk of both stroke and bleeding? Atrial fibrillation: current management. Dialogues Cardiovasc Med 17:197–205 Kirchhof P (2012) How do we balance risk and benefit in a population at risk of both stroke and bleeding? Atrial fibrillation: current management. Dialogues Cardiovasc Med 17:197–205
[13]
Zurück zum Zitat Granger CB, Alexander JH, McMurray JJ et al (2011) Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 365:981–992 CrossRefPubMed Granger CB, Alexander JH, McMurray JJ et al (2011) Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 365:981–992 CrossRefPubMed
[14]
Zurück zum Zitat Patel MR, Mahaffey KW, Garg J et al (2011) Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 365:883–891 CrossRefPubMed Patel MR, Mahaffey KW, Garg J et al (2011) Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 365:883–891 CrossRefPubMed
[15]
Zurück zum Zitat Connolly SJ, Ezekowitz MD, Yusuf S et al (2009) Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 361:1139–1151 CrossRefPubMed Connolly SJ, Ezekowitz MD, Yusuf S et al (2009) Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 361:1139–1151 CrossRefPubMed
[16]
Zurück zum Zitat Connolly S, Eikelboom J, Joyner C et al (2011) Apixaban in patients with atrial fibrillation. N Engl J Med 364:806–817 CrossRefPubMed Connolly S, Eikelboom J, Joyner C et al (2011) Apixaban in patients with atrial fibrillation. N Engl J Med 364:806–817 CrossRefPubMed
[17]
Zurück zum Zitat Gelder IC van, Groenveld HF, Crijns HJ et al (2010) Lenient versus strict rate control in patients with atrial fibrillation. N Engl J Med 362:1363–1373 CrossRefPubMed Gelder IC van, Groenveld HF, Crijns HJ et al (2010) Lenient versus strict rate control in patients with atrial fibrillation. N Engl J Med 362:1363–1373 CrossRefPubMed
[18]
Zurück zum Zitat Calkins H, Kuck KH, Cappato R et al (2012) 2012 HRS/EHRA/ECAS expert consensus statement on catheter and surgical ablation of atrial fibrillation: recommendations for patient selection, procedural techniques, patient management and follow-up, definitions, endpoints, and research trial design. Europace 14:528–606 CrossRefPubMed Calkins H, Kuck KH, Cappato R et al (2012) 2012 HRS/EHRA/ECAS expert consensus statement on catheter and surgical ablation of atrial fibrillation: recommendations for patient selection, procedural techniques, patient management and follow-up, definitions, endpoints, and research trial design. Europace 14:528–606 CrossRefPubMed
[19]
Zurück zum Zitat Jahangir A, Lee V, Friedman PA et al (2007) Long-term progression and outcomes with aging in patients with lone atrial fibrillation: a 30-year follow-up study. Circulation 115:3050–3056 CrossRefPubMed Jahangir A, Lee V, Friedman PA et al (2007) Long-term progression and outcomes with aging in patients with lone atrial fibrillation: a 30-year follow-up study. Circulation 115:3050–3056 CrossRefPubMed
[20]
Zurück zum Zitat Lown B, Perlroth M, Kaidbey S et al (1963) Cardioversion of atrial fibrillation. A report on the treatment of 65 episodes in 59 patients. N Engl J Med 269:325–331 CrossRefPubMed Lown B, Perlroth M, Kaidbey S et al (1963) Cardioversion of atrial fibrillation. A report on the treatment of 65 episodes in 59 patients. N Engl J Med 269:325–331 CrossRefPubMed
[21]
Zurück zum Zitat Kirchhof P, Eckardt L, Loh P et al (2002) Anterior-posterior versus anterior-lateral electrode positions for external cardioversion of atrial fibrillation: a randomised trial. Lancet 360:1275–1279 CrossRefPubMed Kirchhof P, Eckardt L, Loh P et al (2002) Anterior-posterior versus anterior-lateral electrode positions for external cardioversion of atrial fibrillation: a randomised trial. Lancet 360:1275–1279 CrossRefPubMed
[22]
Zurück zum Zitat Kirchhof P, Mönnig G, Wasmer K et al (2005) A trial of self-adhesive patch electrodes and hand-held paddle electrodes for external cardioversion of atrial fibrillation (MOBIPAPA). Eur Heart J 26:1292–1297 CrossRefPubMed Kirchhof P, Mönnig G, Wasmer K et al (2005) A trial of self-adhesive patch electrodes and hand-held paddle electrodes for external cardioversion of atrial fibrillation (MOBIPAPA). Eur Heart J 26:1292–1297 CrossRefPubMed
[23]
Zurück zum Zitat Schotten U, Verheule S, Kirchhof P, Goette A (2011) Pathophysiological mechanisms of atrial fibrillation: a translational appraisal. Physiol Rev 91:265–325 CrossRefPubMed Schotten U, Verheule S, Kirchhof P, Goette A (2011) Pathophysiological mechanisms of atrial fibrillation: a translational appraisal. Physiol Rev 91:265–325 CrossRefPubMed
[24]
Zurück zum Zitat Kirchhof P, Andresen D, Bosch R et al (2012) Short-term versus long-term antiarrhythmic drug treatment after cardioversion of atrial fibrillation (Flec-SL): a prospective, randomised, open-label, blinded endpoint assessment trial. Lancet 380:238–246 CrossRefPubMed Kirchhof P, Andresen D, Bosch R et al (2012) Short-term versus long-term antiarrhythmic drug treatment after cardioversion of atrial fibrillation (Flec-SL): a prospective, randomised, open-label, blinded endpoint assessment trial. Lancet 380:238–246 CrossRefPubMed
[25]
Zurück zum Zitat Apostolakis S, Oeff M, Tebbe U et al (2013) Flecainide acetate for the treatment of atrial and ventricular arrhythmias. Expert Opin Pharmacother 14:347–357 CrossRefPubMed Apostolakis S, Oeff M, Tebbe U et al (2013) Flecainide acetate for the treatment of atrial and ventricular arrhythmias. Expert Opin Pharmacother 14:347–357 CrossRefPubMed
[26]
Zurück zum Zitat Connolly SJ (1999) Evidence-based analysis of amiodarone efficacy and safety. Circulation 100:2025–2034 CrossRefPubMed Connolly SJ (1999) Evidence-based analysis of amiodarone efficacy and safety. Circulation 100:2025–2034 CrossRefPubMed
[27]
Zurück zum Zitat Ahmed S, Rienstra M, Crijns HJ et al (2008) Continuous vs episodic prophylactic treatment with amiodarone for the prevention of atrial fibrillation: a randomized trial. JAMA 300:1784–1792 CrossRefPubMed Ahmed S, Rienstra M, Crijns HJ et al (2008) Continuous vs episodic prophylactic treatment with amiodarone for the prevention of atrial fibrillation: a randomized trial. JAMA 300:1784–1792 CrossRefPubMed
[28]
Zurück zum Zitat Fabritz L, Kirchhof P (2010) Predictable and less predictable unwanted cardiac drugs effects: individual pre-disposition and transient precipitating factors. Basic Clin Pharmacol Toxicol 106:263–268 CrossRefPubMed Fabritz L, Kirchhof P (2010) Predictable and less predictable unwanted cardiac drugs effects: individual pre-disposition and transient precipitating factors. Basic Clin Pharmacol Toxicol 106:263–268 CrossRefPubMed
[29]
Zurück zum Zitat Haissaguerre M, Jais P, Shah DC et al (1998) Spontaneous initiation of atrial fibrillation by ectopic beats originating in the pulmonary veins. N Engl J Med 339:659–666 CrossRefPubMed Haissaguerre M, Jais P, Shah DC et al (1998) Spontaneous initiation of atrial fibrillation by ectopic beats originating in the pulmonary veins. N Engl J Med 339:659–666 CrossRefPubMed
[30]
Zurück zum Zitat Engdahl J, Andersson L, Mirskaya M, Rosenqvist M (2013) Stepwise screening of atrial fibrillation in a 75-year-old population: implications for stroke prevention. Circulation 127:930–937 CrossRefPubMed Engdahl J, Andersson L, Mirskaya M, Rosenqvist M (2013) Stepwise screening of atrial fibrillation in a 75-year-old population: implications for stroke prevention. Circulation 127:930–937 CrossRefPubMed
[31]
Zurück zum Zitat Ritter MA, Kochhauser S, Duning T et al (2013) Occult atrial fibrillation in cryptogenic stroke: detection by 7-day electrocardiogram versus implantable cardiac monitors. Stroke 44:1449–1452 CrossRefPubMed Ritter MA, Kochhauser S, Duning T et al (2013) Occult atrial fibrillation in cryptogenic stroke: detection by 7-day electrocardiogram versus implantable cardiac monitors. Stroke 44:1449–1452 CrossRefPubMed
[32]
Zurück zum Zitat Healey JS, Connolly SJ, Gold MR et al (2012) Subclinical atrial fibrillation and the risk of stroke. N Engl J Med 366:120–129 CrossRefPubMed Healey JS, Connolly SJ, Gold MR et al (2012) Subclinical atrial fibrillation and the risk of stroke. N Engl J Med 366:120–129 CrossRefPubMed
Metadaten
Titel
Diagnostik und Behandlung von Vorhofflimmern
Aktuelle Empfehlungen für die Praxis
verfasst von
Prof. Dr. Paulus Kirchhof
Publikationsdatum
22.03.2015
Verlag
Springer-Verlag
Erschienen in
CME / Ausgabe 3/2015
Print ISSN: 1614-371X
Elektronische ISSN: 1614-3744
DOI
https://doi.org/10.1007/s11298-015-1100-8

Weitere Artikel der Ausgabe 3/2015

CME 3/2015 Zur Ausgabe

Schwerpunkt_Atemwegserkrankungen

Atemwegsinfekte bei Kindern: Phytos fördern!

Neu im Fachgebiet Allgemeinmedizin

Newsletter

Bestellen Sie unseren kostenlosen Newsletter Update Allgemeinmedizin und bleiben Sie gut informiert – ganz bequem per eMail.